Science & Research
Healthy Food Delivery Programs Improve Quality of Life for Heart Failure Patients, Study Finds
A new study shows that providing medically tailored meals or fresh produce alongside dietary counseling significantly improves quality of life for heart failure patients following hospitalization, highlighting the potential of food-based interventions in chronic disease management.
Stress Cardiac MRI Testing Improves Angina Diagnosis and Patient Outcomes, Study Finds
New research presented at the American Heart Association's Scientific Sessions 2025 demonstrates that stress cardiac MRI testing significantly improves diagnosis accuracy and quality of life for patients with chest pain despite clear coronary arteries.
Study Finds Prasugrel May Offer Better Outcomes Than Ticagrelor for Diabetic Patients With Stents
New research presented at the American Heart Association's Scientific Sessions 2025 suggests prasugrel may be more effective than ticagrelor at preventing heart attacks, strokes, bleeding complications and death in diabetic patients who received coronary stents, challenging current interchangeable use of these antiplatelet medications.
GeoVax Emphasizes Vaccine Innovation and Trust Building on World Immunization Day
GeoVax Labs is advancing next-generation multi-antigen vaccines and U.S. manufacturing capabilities to address declining public confidence in newer vaccines while protecting vulnerable populations.
Educator-Researcher Advocates for Broader Legitimacy Standards in Global Higher Education
Count Jonathan of Aquitaine's research challenges rigid academic accreditation norms by advocating for more inclusive educational models that maintain rigor while serving diverse global communities.
Family-Based Program Reduces Blood Pressure by 10 mm Hg in Rural Chinese Communities
A family-focused health intervention in rural China achieved significant blood pressure reductions through community support and lifestyle changes, offering a scalable model for cardiovascular disease prevention in resource-limited areas.
Financial Incentives Double Blood Pressure Medication Use But Fail to Improve Health Outcomes
A new study reveals that while daily cash rewards doubled medication adherence among high blood pressure patients, the improved compliance did not translate to better blood pressure control, highlighting the complexity of long-term behavior change.
Food Delivery and Dietary Counseling Program Shows Promise in Reducing Blood Pressure for Black Adults in Food Deserts
A study presented at the American Heart Association's Scientific Sessions 2025 demonstrates that providing home-delivered groceries and dietary counseling significantly improved blood pressure and cholesterol levels in Black adults living in food deserts, though benefits disappeared when support ended, highlighting the need for sustained interventions to address food access barriers.
American Heart Association Launches National Initiative to Combat Rising Heart Valve Disease Deaths
The American Heart Association has launched a comprehensive Heart Valve Initiative to address the growing mortality from heart valve disease, which affects over 28 million people worldwide and contributes to more than 60,000 annual U.S. deaths through improved diagnosis, treatment protocols, and public awareness.
Tailored Vitamin D Doses Reduce Heart Attack Risk by 52% in Heart Disease Patients
Adults with heart disease who received personalized vitamin D supplementation to achieve optimal blood levels experienced more than half the risk of heart attack compared to those without vitamin D monitoring, according to preliminary research presented at the American Heart Association's Scientific Sessions 2025.
Daily Coffee Consumption Linked to Reduced AFib Recurrence in New Clinical Trial
A new clinical trial reveals that adults with atrial fibrillation who drank one cup of coffee daily were 39% less likely to experience recurrent AFib episodes, challenging conventional medical advice about caffeine avoidance for heart rhythm patients.
Earlier Blood Transfusions May Reduce Heart Failure Risk in Cardiac Patients After Surgery
A new study suggests that transfusing blood earlier in patients with heart disease undergoing major surgery may significantly reduce the risk of heart failure and irregular heartbeat without increasing severe complication rates.
Catheter Ablation May Eliminate Need for Blood Thinners in Some AFib Patients, Study Finds
New research suggests successful catheter ablation for atrial fibrillation reduces stroke risk enough that many patients can safely discontinue potent blood thinners in favor of aspirin, potentially reducing bleeding complications while maintaining stroke protection.
Shorter Clot-Prevention Therapy After Stent Placement Proves Effective for AFib Patients
New research shows a one-month course of dual clot-preventing therapy followed by single medication treatment is as effective as year-long dual therapy for preventing stroke, heart attack and death in atrial fibrillation patients with stents, while significantly reducing bleeding complications.
Standard Medical Care Outperforms Minimally Invasive Procedure for High-Risk Atrial Fibrillation Patients
New research presented at the American Heart Association's Scientific Sessions 2025 found that standard medical care, including blood thinners when appropriate, proved more effective than a catheter-based procedure for preventing stroke and other complications in older atrial fibrillation patients at high risk of bleeding and stroke.
Oral Cholesterol Medication Shows Promise as Alternative to Injectable Treatments
A new daily oral medication called enlicitide demonstrated up to 60% reduction in LDL cholesterol in clinical trials, potentially offering a more convenient option for high-risk patients who struggle to reach cholesterol targets with current treatments.
PCSK9 Inhibitor Shows Significant Cardiovascular Risk Reduction in High-Risk Patients Without Prior Heart Events
The VESALIUS-CV trial demonstrates that evolocumab reduces major cardiovascular events by 25% in patients with atherosclerotic disease or diabetes who haven't had prior heart attacks or strokes, potentially expanding preventive treatment options for millions at risk.
Novel Triple-Receptor Medication Shows Promise for Severe Triglyceride Reduction and Liver Health
A new investigational medication called DR10624 demonstrated significant reductions in triglyceride levels and liver fat in patients with severe hypertriglyceridemia, potentially offering a new treatment approach for a condition with limited current options.
Immune Cell Surface Sugar Shedding Identified as Key Factor in Psoriasis Progression
New research reveals immune cells shed surface sugars before entering inflamed skin in psoriasis patients, potentially opening new treatment pathways for the chronic autoimmune condition.
Oncotelic Therapeutics Venture Advances Novel Breast Cancer Treatment to Clinical Trials
Sapu Nano, an Oncotelic Therapeutics venture, has received Australian ethics approval to begin clinical trials for Sapu003, an injectable form of everolimus that could significantly improve breast cancer treatment outcomes by enabling full drug absorption through intravenous delivery.
Scientific Integrity Concerns Raised Over CERN's $16 Billion Trigger System at International Conference
The Crosetto Foundation has revealed evidence that CERN's $16 billion FPGA-based trigger system cannot meet technical requirements for the High-Luminosity Large Hadron Collider, calling for funding suspension until scientific questions are resolved.
Soligenix Reports Q3 2025 Results with Key Clinical Milestones for Rare Disease Treatments
Soligenix Inc. announced positive clinical progress for its rare disease pipeline including upcoming Phase 2a psoriasis results and maintained safety profile for HyBryte™ in CTCL treatment, supported by sufficient funding through 2026.
MAX Power Mining Drills Canada's First Natural Hydrogen Well in Saskatchewan
MAX Power Mining has commenced drilling Canada's inaugural natural hydrogen well in Saskatchewan, marking a significant milestone in the country's clean energy transition and positioning the company as a leader in this emerging sector.
TheSoulOf.AI and Alicia Kali Institute Unveil Six Tiers of Sentience Framework for Advanced AI
TheSoulOf.AI and Alicia Kali Institute have developed a Six Tiers of Sentience framework that defines progressive levels of awareness in AI systems, representing a significant advancement in creating transparent, safe, and emotionally intelligent artificial intelligence that could transform human-AI interaction.
Soligenix Advances Psoriasis Treatment SGX302 with Promising Early Clinical Results
Soligenix is progressing its phase 2a clinical trial of SGX302 for psoriasis treatment, showing encouraging safety and biological activity data that positions the therapy to address a $67 billion global market opportunity.
Annovis Bio Completes Site Activation and Marks First Patient Completions in Pivotal Alzheimer's Phase 3 Trial
Annovis Bio has fully activated all 84 U.S. sites for its pivotal Phase 3 Alzheimer's trial and achieved first patient completions, positioning the company to deliver symptomatic data by late 2026 for its potential neurodegenerative disease therapy buntanetap.
Study Reveals Neurocognitive Decline in CNS Cancer Patients, Highlighting Treatment Challenges
Recent research demonstrates significant neurocognitive decline in central nervous system cancer patients, emphasizing the critical need for therapies that address both tumor control and cognitive preservation.
MIT and Harvard Researchers Develop Enhanced Natural Killer Cell Therapy for Cancer Treatment
Researchers from MIT and Harvard Medical School have engineered modified natural killer cells that show promising results in fighting cancer while avoiding immune system rejection, potentially transforming cancer immunotherapy approaches.
Cybin Inc. to Present at Guggenheim Healthcare Innovation Conference Amid Phase 3 Mental Health Drug Development
Cybin Inc. announced its participation in the Guggenheim Healthcare Innovation Conference as the company advances its Phase 3 clinical trials for novel mental health treatments, highlighting growing investor interest in innovative neuropsychiatry solutions.
NanoViricides Sets 2025 Annual Shareholders Meeting Amid Clinical Development Push
NanoViricides announced its 2025 shareholders meeting while advancing multiple antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.